Elevance Health lowers its 2025 profit outlook due to higher ACA and Medicaid costs driven by sicker patients and increased care utilization, reflecting an industry-wide trend. Analysts anticipate persistent insurer losses before improvement in 2026.

HHS and CMS unveil Most Favored Nation drug pricing model targeting pharmaceutical manufacturers to align U.S. drug prices with international benchmarks and reduce costs.